Establishment of a novel safety assessment method for vaccine adjuvant development. Issue 46 (12th November 2018)

• Record Type: Journal Article
• Authors: Sasaki, Eita; Momose, Haruka; Hiradate, Yuki; Mizukami, Takuo; Hamaguchi, Isao
• Is Part Of: Vaccine. Volume 36:Issue 46(2018)
• Page Start: 7112
• Page End: 7118
• Publication Date: 2018-11-12
• Subjects: Adjuvant -- Influenza vaccine -- Safety evaluation -- Genomics -- Biomarker -- Preclinical test; Alum aluminum salts -- HA hemagglutinin -- HAL human leukocyte antigen -- IFN interferon -- IL interleukin -- LPS lipopolysaccharide -- LT Escherichia coli heat–labile toxin -- MPL monophosphoryl lipid A -- NALT nasal–associated lymphoid tissue -- QGP QuantiGene Plex -- SA saline -- SIV split type influenza vaccine -- Th T helper cells -- TLR Toll–like receptor -- WBC white blood cells -- WIV whole virion-inactivated influenza vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.10.009
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Late-stage vaccine adjuvant safety testing leads to candidate drop out. Early, quantitative testing can facilitate the development of safe adjuvants. Novel biomarker genes have been identified for influenza vaccine adjuvant testing. The safety testing method is suitable for rapid, quantitative screening. Abstract: Vaccines effectively prevent infectious diseases. Many types of vaccines against various pathogens that threaten humans are currently in widespread use. Recently, adjuvant adaptation has been attempted to activate innate immunity to enhance the effectiveness of vaccines. The effectiveness of adjuvants for vaccinations has been demonstrated in many animal models and clinical trials. Although a highly potent adjuvant tends to have high effectiveness, it also has the potential to increase the risk of side effects such as pain, edema, and fever. Indeed, highly effective adjuvants, such as poly(I:C), have not been clinically applied due to their high risks of toxicity in humans. Therefore, the task in the field of adjuvant development is to clinically apply highly effective and non- or low-toxic adjuvant-containing vaccines. To resolve this issue, it is essential to ensure a low risk of side effects and the high efficacy of an adjuvant in the early developmental phases. This review summarizes the theory and history of the current safety assessment methods for adjuvants, using the inactivated influenza vaccine as a model. Our novel method was developed as a system to judge the safety of a candidate compound using biomarkers identified by genomic technology and statistical tools. A systematic safety assessment tool for adjuvants would be of great use for predicting toxicity during novel adjuvant development, screening, and quality control.